NextGen Bio
Filter News
Found 7,197 articles
-
As BioSpace proudly introduces our 2022 Hotbed Maps, let’s explore the industry’s most thriving territories, research leading employers and search for relevant jobs on BioSpace.
-
BioSpace is proud to present its NextGen Bio “Class of 2022,” a list of up-and-coming life sciences companies in North America that recently launched.
-
Graphite Bio Announces Participation in Upcoming Investor Conferences - Jan 27, 2022
1/27/2022
Graphite Bio, Inc., a clinical-stage, next-generation gene editing company focused on therapies that harness targeted gene integration to treat or cure serious diseases, announced participation in the following upcoming investor conferences.
-
Money on the Move: January 19 – 25
1/26/2022
Temps are falling and so is investor cash. Here's which biotech companies are scooping up the dollars this week. -
Kriya Licenses Next Generation Complement-Targeted Gene Therapies for the Treatment of Geographic Atrophy and Other Ocular Diseases
1/26/2022
Kriya Therapeutics, Inc. today announced an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.
-
The Biotechnology Innovation Organization provides a glimpse of economic development in the biosciences ecosystem at the state and regional levels.
-
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-868 for the Treatment of Advanced Solid Tumors
1/20/2022
Nuvation Bio Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared its investigational new drug (IND) application to evaluate NUV-868.
-
Enveda Biosciences believes the answers to humanity’s most challenging diseases can be found by harnessing the complexity of the natural world.
-
Immuneering Strengthens Board of Directors with the Appointment of Diana F. Hausman, M.D.Industry Executive Brings More than 20 Years of Clinical Drug Development Expertise
1/18/2022
Immuneering Corporation today announced the appointment of Diana F. Hausman, M.D., Chief Medical Officer of Lengo Therapeutics (a wholly-owned subsidiary of Blueprint Medicines Corporation), to its Board of Directors.
-
Triumvira Immunologics Establishes Scientific Advisory Board
1/18/2022
Triumvira Immunologics today announced that the company formed its inaugural Scientific Advisory Board (SAB), comprising four leading scientists and physicians.
-
Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer
1/11/2022
Neogene Therapeutics, Inc. today announced an exclusive, worldwide license agreement with the National Cancer Institute (NCI) for a portfolio of TCRs targeting KRAS and TP53 mutations for the treatment of patients with cancer.
-
Sana Biotechnology Obtains Exclusive License from National Institutes of Health for CD22 CAR Construct
1/11/2022
Sana Biotechnology, Inc. announced that the company entered into an agreement with the National Cancer Institution, an institute of the National Institutes of Health, for worldwide exclusive commercial rights to the NIH’s CD22 chimeric antigen receptor with a fully-human binder for use in certain in vivo gene therapy and ex vivo allogeneic CAR T applications for B cell malignancies.
-
Forge Biologics Closes $80 Million in Additional Financing to Accelerate Planned CDMO Expansion
1/10/2022
Forge Biologics announced today 2022 manufacturing expansion plans to meet the growing demand for gene therapy manufacturing.
-
Nuvation Bio Provides Corporate Update and Highlights Key 2022 Milestones
1/10/2022
Nuvation Bio Inc. provided a corporate update and highlighted key 2022 milestones in anticipation of its presentation at the 40th Annual J.P. Morgan Healthcare Conference being held virtually January 10 – 13, 2022.
-
Omega Therapeutics Announces Appointment of Yan Moore, M.D., as Chief Medical Officer
1/10/2022
Omega Therapeutics, Inc. announced the appointment of Yan Moore, M.D., as Chief Medical Officer.
-
Kriya Expands Gene Therapy Pipeline and Establishes Its Rare Disease Therapeutic Area Division With the Acquisition of Warden Bio
1/7/2022
Kriya Therapeutics, Inc. announced today that it has acquired Warden Bio, a company developing novel AAV-mediated gene therapies for glycogen storage disorders (GSDs).
-
This partnership is representative of the rapidly growing high throughput sector of the proteomics market.
-
Shape Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
1/6/2022
Shape Therapeutics Inc. will present virtually at the 40th Annual J.P. Morgan Healthcare Conference.
-
Korro Bio Completes $116M Series B Financing to Expand the Frontier of Genetic Medicine Through Its Pipeline of RNA Editing Programs
1/5/2022
Financing led by Eventide Asset Management with participation from a strong syndicate of new and existing investors.
-
Werewolf Therapeutics to Present at the H.C. Wainwright Bioconnect Conference
1/5/2022
Werewolf Therapeutics, Inc. announced that management will present at the H.C. Wainwright Bioconnect Conference, taking place virtually from January 10-13, 2022.